Quick Answer
Regen BioPharma Inc reported Operating Income Loss of -$338.5 thousand for the year ending 2025.
- Regen BioPharma Inc showed an increase of +18.9% in Operating Income Loss from 2024 to 2025.
- This data is from Regen BioPharma Inc's annual report (Form 10-K), filed with the SEC on December 30, 2025.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), Regen BioPharma Inc's Operating Income Loss has declined by 5.8%.
- Historical annual values: Fiscal year 2025: -$338.5 thousand | Fiscal year 2024: -$417.2 thousand | Fiscal year 2023: -$687.0 thousand | Fiscal year 2022: -$339.6 thousand | Fiscal year 2021: -$200.8 thousand | Fiscal year 2020: -$209.3 thousand | Fiscal year 2019: -$756.8 thousand | Fiscal year 2018: -$1.43 million | Fiscal year 2017: -$2.51 million | Fiscal year 2016: -$2.96 million | Fiscal year 2015: -$1.98 million | Fiscal year 2014: -$706.4 thousand | Fiscal year 2013: -$319.8 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: